Traws Pharma
TRAW
9 hedge funds and large institutions have $5.71M invested in Traws Pharma in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,625% more capital inflows, than outflows
Capital inflows: $2.72M | Capital outflows: $158K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
6.26% more ownership
Funds ownership: 21.59% → 27.85% (+6.3%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
+$1.04M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$882K |
| 3 |
6CM
683 Capital Management
New York
|
+$683K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.5K |
| 5 |
Panagora Asset Management
Boston,
Massachusetts
|
+$24.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Weiss Multi-Strategy Advisers
New York
|
-$68K |
| 2 |
Virtu KCG Holdings
New York
|
-$36K |
| 3 |
Boxer Capital
San Diego,
California
|
-$24.8K |
| 4 |
Renaissance Technologies
New York
|
-$24.8K |
| 5 |
Morgan Stanley
New York
|
-$4K |
TRAW Hedge Fund Activity: Q2 2017 in Review
9 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2017, worth a combined $5.71M — up 29% from $4.44M a quarter earlier.
Fund positioning in TRAW was balanced in Q2 2017: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Tyndall Capital Partners, adding an estimated $1.04M. The largest seller was Weiss Multi-Strategy Advisers, exiting entirely with an estimated $68K sold.
- 9 institutional investors held Traws Pharma (TRAW) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $5.71M of Traws Pharma stock for Q2 2017, up 29% quarter-over-quarter.
- 2 funds opened new Traws Pharma positions in Q2 2017 and 2 closed out, a net change of 0 holders.
- The largest Traws Pharma buyer in Q2 2017 was Tyndall Capital Partners, an estimated $1.04M added.
- The largest Traws Pharma seller in Q2 2017 was Weiss Multi-Strategy Advisers, an estimated $68K sold.
Based on aggregated 13F filings for Q2 2017.